APO Research
Talk to an analyst

APO RESEARCH · REPORT

Angiogenesis Modulators

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Angiogenesis Modulators Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025194 pages

Choose your research edition.

Industry ResearchAngiogenesis Modulators Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Angiogenesis Modulators Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Angiogenesis Modulators Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Angiogenesis Modulators Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Angiogenesis Modulators Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Angiogenesis Modulators market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Angiogenesis Modulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Angiogenesis Modulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Angiogenesis Modulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Angiogenesis Modulators is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Angiogenesis Modulators include Bayer Pharma AG (Germany), Bionomics Ltd. (Australia), CASI Pharmaceuticals, Inc. (USA), Celgene Corporation (USA), F.Hoffmann-La Roche AG (Switzerland), Genentech, Inc. (USA), AstraZeneca plc (UK), Amgen, Inc. (USA) and GlaxoSmithKline plc (UK), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Angiogenesis Modulators market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Angiogenesis Modulators and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Angiogenesis Modulators sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Angiogenesis Modulators market size, projected growth trends, production technologies, key applications, and end-use industries.

Angiogenesis Modulators Segment by Company

Bayer Pharma AG (Germany)

Bionomics Ltd. (Australia)

CASI Pharmaceuticals, Inc. (USA)

Celgene Corporation (USA)

F.Hoffmann-La Roche AG (Switzerland)

Genentech, Inc. (USA)

AstraZeneca plc (UK)

Amgen, Inc. (USA)

GlaxoSmithKline plc (UK)

Eli Lilly and Company (USA)

Eisai (Japan)

Angiogenesis Modulators Segment by Type

Angiogenesis Stimulators

Angiogenin

Angiogenesis Inhibitors

Others

Angiogenesis Modulators Segment by Application

Breast Cancer

Prostate Cancer

Colorectal Cancer

Lung Cancer

Others

Angiogenesis Modulators Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Angiogenesis Modulators market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Angiogenesis Modulators and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Angiogenesis Modulators.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Angiogenesis Modulators market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Angiogenesis Modulators manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Angiogenesis Modulators in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Angiogenesis Modulators in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Angiogenesis Modulators Industry Trends Table 2. Angiogenesis Modulators Industry Drivers Table 3. Angiogenesis Modulators Industry Opportunities and Challenges Table 4. Angiogenesis Modulators Industry Restraints Table 5. Global Angiogenesis Modulators Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Angiogenesis Modulators Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Angiogenesis Modulators Sales by Manufacturers (k tons) & (2021-2026) Table 8. Global Angiogenesis Modulators Sales Market Share by Manufacturers Table 9. Global Angiogenesis Modulators Average Sales Price (US$/ton) of Manufacturers (2021-2026) Table 10. Global Angiogenesis Modulators Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Angiogenesis Modulators Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Angiogenesis Modulators Manufacturers, Product Type & Application Table 13. Global Angiogenesis Modulators Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Angiogenesis Modulators by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Angiogenesis Stimulators Table 17. Major Manufacturers of Angiogenin Table 18. Major Manufacturers of Angiogenesis Inhibitors Table 19. Major Manufacturers of Others Table 20. Global Angiogenesis Modulators Sales by Type 2021 VS 2025 VS 2032 (k tons) Table 21. Global Angiogenesis Modulators Sales by Type (2021-2026) & (k tons) Table 22. Global Angiogenesis Modulators Sales by Type (2027-2032) & (k tons) Table 23. Global Angiogenesis Modulators Sales Market Share by Type (2021-2026) Table 24. Global Angiogenesis Modulators Sales Market Share by Type (2027-2032) Table 25. Global Angiogenesis Modulators Revenue by Type 2021 VS 2025 VS 2032 (k tons) Table 26. Global Angiogenesis Modulators Revenue by Type (2021-2026) & (k tons) Table 27. Global Angiogenesis Modulators Revenue by Type (2027-2032) & (k tons) Table 28. Global Angiogenesis Modulators Revenue Market Share by Type (2021-2026) Table 29. Global Angiogenesis Modulators Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Breast Cancer Table 31. Major Manufacturers of Prostate Cancer Table 32. Major Manufacturers of Colorectal Cancer Table 33. Major Manufacturers of Lung Cancer Table 34. Major Manufacturers of Others Table 35. Global Angiogenesis Modulators Sales by Application 2021 VS 2025 VS 2032 (k tons) Table 36. Global Angiogenesis Modulators Sales by Application (2021-2026) & (k tons) Table 37. Global Angiogenesis Modulators Sales by Application (2027-2032) & (k tons) Table 38. Global Angiogenesis Modulators Sales Market Share by Application (2021-2026) Table 39. Global Angiogenesis Modulators Sales Market Share by Application (2027-2032) Table 40. Global Angiogenesis Modulators Revenue by Application 2021 VS 2025 VS 2032 (k tons) Table 41. Global Angiogenesis Modulators Revenue by Application (2021-2026) & (k tons) Table 42. Global Angiogenesis Modulators Revenue by Application (2027-2032) & (k tons) Table 43. Global Angiogenesis Modulators Revenue Market Share by Application (2021-2026) Table 44. Global Angiogenesis Modulators Revenue Market Share by Application (2027-2032) Table 45. Global Angiogenesis Modulators Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 46. Global Angiogenesis Modulators Sales by Region (2021-2026) & (k tons) Table 47. Global Angiogenesis Modulators Sales Market Share by Region (2021-2026) Table 48. Global Angiogenesis Modulators Sales Forecasted by Region (2027-2032) & (k tons) Table 49. Global Angiogenesis Modulators Sales Forecasted Market Share by Region (2027-2032) Table 50. North America Angiogenesis Modulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 51. North America Angiogenesis Modulators Sales by Country (2021-2026) & (k tons) Table 52. North America Angiogenesis Modulators Sales by Country (2027-2032) & (k tons) Table 53. Europe Angiogenesis Modulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 54. Europe Angiogenesis Modulators Sales by Country (2021-2026) & (k tons) Table 55. Europe Angiogenesis Modulators Sales by Country (2027-2032) & (k tons) Table 56. Asia Pacific Angiogenesis Modulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 57. Asia Pacific Angiogenesis Modulators Sales by Country (2021-2026) & (k tons) Table 58. Asia Pacific Angiogenesis Modulators Sales by Country (2027-2032) & (k tons) Table 59. South America, Middle East and Africa Angiogenesis Modulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k tons) Table 60. South America, Middle East and Africa Angiogenesis Modulators Sales by Country (2021-2026) & (k tons) Table 61. South America, Middle East and Africa Angiogenesis Modulators Sales by Country (2027-2032) & (k tons) Table 62. Global Angiogenesis Modulators Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global Angiogenesis Modulators Revenue by Region (2021-2026) & (US$ Million) Table 64. Global Angiogenesis Modulators Revenue by Region (2027-2032) & (US$ Million) Table 65. Global Angiogenesis Modulators Revenue Market Share by Region (2021-2026) Table 66. Global Angiogenesis Modulators Revenue Market Share by Region (2027-2032) Table 67. Bayer Pharma AG (Germany) Company Information Table 68. Bayer Pharma AG (Germany) Business Overview Table 69. Bayer Pharma AG (Germany) Angiogenesis Modulators Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Bayer Pharma AG (Germany) Angiogenesis Modulators Product Portfolio Table 71. Bayer Pharma AG (Germany) Recent Development Table 72. Bionomics Ltd. (Australia) Company Information Table 73. Bionomics Ltd. (Australia) Business Overview Table 74. Bionomics Ltd. (Australia) Angiogenesis Modulators Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Bionomics Ltd. (Australia) Angiogenesis Modulators Product Portfolio Table 76. Bionomics Ltd. (Australia) Recent Development Table 77. CASI Pharmaceuticals, Inc. (USA) Company Information Table 78. CASI Pharmaceuticals, Inc. (USA) Business Overview Table 79. CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Product Portfolio Table 81. CASI Pharmaceuticals, Inc. (USA) Recent Development Table 82. Celgene Corporation (USA) Company Information Table 83. Celgene Corporation (USA) Business Overview Table 84. Celgene Corporation (USA) Angiogenesis Modulators Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Celgene Corporation (USA) Angiogenesis Modulators Product Portfolio Table 86. Celgene Corporation (USA) Recent Development Table 87. F.Hoffmann-La Roche AG (Switzerland) Company Information Table 88. F.Hoffmann-La Roche AG (Switzerland) Business Overview Table 89. F.Hoffmann-La Roche AG (Switzerland) Angiogenesis Modulators Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. F.Hoffmann-La Roche AG (Switzerland) Angiogenesis Modulators Product Portfolio Table 91. F.Hoffmann-La Roche AG (Switzerland) Recent Development Table 92. Genentech, Inc. (USA) Company Information Table 93. Genentech, Inc. (USA) Business Overview Table 94. Genentech, Inc. (USA) Angiogenesis Modulators Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Genentech, Inc. (USA) Angiogenesis Modulators Product Portfolio Table 96. Genentech, Inc. (USA) Recent Development Table 97. AstraZeneca plc (UK) Company Information Table 98. AstraZeneca plc (UK) Business Overview Table 99. AstraZeneca plc (UK) Angiogenesis Modulators Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. AstraZeneca plc (UK) Angiogenesis Modulators Product Portfolio Table 101. AstraZeneca plc (UK) Recent Development Table 102. Amgen, Inc. (USA) Company Information Table 103. Amgen, Inc. (USA) Business Overview Table 104. Amgen, Inc. (USA) Angiogenesis Modulators Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Amgen, Inc. (USA) Angiogenesis Modulators Product Portfolio Table 106. Amgen, Inc. (USA) Recent Development Table 107. GlaxoSmithKline plc (UK) Company Information Table 108. GlaxoSmithKline plc (UK) Business Overview Table 109. GlaxoSmithKline plc (UK) Angiogenesis Modulators Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. GlaxoSmithKline plc (UK) Angiogenesis Modulators Product Portfolio Table 111. GlaxoSmithKline plc (UK) Recent Development Table 112. Eli Lilly and Company (USA) Company Information Table 113. Eli Lilly and Company (USA) Business Overview Table 114. Eli Lilly and Company (USA) Angiogenesis Modulators Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 115. Eli Lilly and Company (USA) Angiogenesis Modulators Product Portfolio Table 116. Eli Lilly and Company (USA) Recent Development Table 117. Eisai (Japan) Company Information Table 118. Eisai (Japan) Business Overview Table 119. Eisai (Japan) Angiogenesis Modulators Sales (k tons), Price (US$/ton), Revenue (US$ Million) and Gross Margin (2021-2026) Table 120. Eisai (Japan) Angiogenesis Modulators Product Portfolio Table 121. Eisai (Japan) Recent Development Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Angiogenesis Modulators Distributors List Table 125. Angiogenesis Modulators Customers List Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Angiogenesis Modulators Product Image Figure 2. Global Angiogenesis Modulators Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Angiogenesis Modulators Market Size (2021-2032) & (US$ Million) Figure 4. Global Angiogenesis Modulators Sales (2021-2032) & (k tons) Figure 5. Global Angiogenesis Modulators Average Price (US$/ton) & (2021-2032) Figure 6. Global Top 5 and 10 Angiogenesis Modulators Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Angiogenesis Stimulators Image Figure 9. Angiogenin Image Figure 10. Angiogenesis Inhibitors Image Figure 11. Others Image Figure 12. Global Angiogenesis Modulators Sales by Type (2021 VS 2025 VS 2032) & (k tons) Figure 13. Global Angiogenesis Modulators Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Angiogenesis Modulators Sales Market Share by Type (2021-2032) Figure 15. Global Angiogenesis Modulators Revenue by Type (2021 VS 2025 VS 2032) & (k tons) Figure 16. Global Angiogenesis Modulators Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Angiogenesis Modulators Revenue Market Share by Type (2021-2032) Figure 18. Breast Cancer Image Figure 19. Prostate Cancer Image Figure 20. Colorectal Cancer Image Figure 21. Lung Cancer Image Figure 22. Others Image Figure 23. Global Angiogenesis Modulators Sales by Application (2021 VS 2025 VS 2032) & (k tons) Figure 24. Global Angiogenesis Modulators Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global Angiogenesis Modulators Sales Market Share by Application (2021-2032) Figure 26. Global Angiogenesis Modulators Revenue by Application (2021 VS 2025 VS 2032) & (k tons) Figure 27. Global Angiogenesis Modulators Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global Angiogenesis Modulators Revenue Market Share by Application (2021-2032) Figure 29. North America Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 30. North America Angiogenesis Modulators Sales Market Share by Country (2021-2032) Figure 31. U.S. Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 32. Canada Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 33. Mexico Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 34. Europe Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 35. Europe Angiogenesis Modulators Sales Market Share by Country (2021-2032) Figure 36. Germany Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 37. France Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 38. U.K. Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 39. Italy Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 40. Netherlands Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 41. Asia Pacific Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 42. Asia Pacific Angiogenesis Modulators Sales Market Share by Country (2021-2032) Figure 43. China Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 44. Japan Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 45. South Korea Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 46. Southeast Asia Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 47. India Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 48. Australia Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 49. South America, Middle East and Africa Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 50. South America, Middle East and Africa Angiogenesis Modulators Sales Market Share by Country (2021-2032) Figure 51. Brazil Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 52. South Africa Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 53. Saudi Arabia Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 54. Turkey Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 55. Argentina Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 56. UAE Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 57. Egypt Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 58. Chile Angiogenesis Modulators Sales and Growth Rate (2021-2032) & (k tons) Figure 59. Global Angiogenesis Modulators Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global Angiogenesis Modulators Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America Angiogenesis Modulators Revenue (2021-2032) & (US$ Million) Figure 62. North America Angiogenesis Modulators Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Angiogenesis Modulators Revenue (2021-2032) & (US$ Million) Figure 64. Europe Angiogenesis Modulators Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific Angiogenesis Modulators Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific Angiogenesis Modulators Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa Angiogenesis Modulators Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa Angiogenesis Modulators Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. Angiogenesis Modulators Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Angiogenesis Modulators Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Angiogenesis Stimulators
  • Angiogenin
  • Angiogenesis Inhibitors
  • Others
Applications
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Lung Cancer
  • Others
Companies covered
  • Bayer Pharma AG (Germany)
  • Bionomics Ltd. (Australia)
  • CASI Pharmaceuticals, Inc. (USA)
  • Celgene Corporation (USA)
  • F.Hoffmann-La Roche AG (Switzerland)
  • Genentech, Inc. (USA)
  • AstraZeneca plc (UK)
  • Amgen, Inc. (USA)
  • GlaxoSmithKline plc (UK)
  • Eli Lilly and Company (USA)
  • Eisai (Japan)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Angiogenesis Modulators Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Angiogenesis Modulators Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Angiogenesis Modulators Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Angiogenesis Modulators Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Angiogenesis Modulators Market Dynamics
  1. 2.1 Angiogenesis Modulators Industry Trends
  2. 2.2 Angiogenesis Modulators Industry Drivers
  3. 2.3 Angiogenesis Modulators Industry Opportunities and Challenges
  4. 2.4 Angiogenesis Modulators Industry Restraints
3 Angiogenesis Modulators Market by Manufacturers
  1. 3.1 Global Angiogenesis Modulators Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Angiogenesis Modulators Sales by Manufacturers (2021-2026)
  3. 3.3 Global Angiogenesis Modulators Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Angiogenesis Modulators Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Angiogenesis Modulators Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Angiogenesis Modulators Manufacturers, Product Type & Application
  7. 3.7 Global Angiogenesis Modulators Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Angiogenesis Modulators Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Angiogenesis Modulators Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Angiogenesis Modulators Tier 1, Tier 2, and Tier 3
4 Angiogenesis Modulators Market by Type
  1. 4.1 Angiogenesis Modulators Type Introduction
  2. 4.1.1 Angiogenesis Stimulators
  3. 4.1.2 Angiogenin
  4. 4.1.3 Angiogenesis Inhibitors
  5. 4.1.4 Others
  6. 4.2 Global Angiogenesis Modulators Sales by Type
  7. 4.2.1 Global Angiogenesis Modulators Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Angiogenesis Modulators Sales by Type (2021-2032)
  9. 4.2.3 Global Angiogenesis Modulators Sales Market Share by Type (2021-2032)
  10. 4.3 Global Angiogenesis Modulators Revenue by Type
  11. 4.3.1 Global Angiogenesis Modulators Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Angiogenesis Modulators Revenue by Type (2021-2032)
  13. 4.3.3 Global Angiogenesis Modulators Revenue Market Share by Type (2021-2032)
5 Angiogenesis Modulators Market by Application
  1. 5.1 Angiogenesis Modulators Application Introduction
  2. 5.1.1 Breast Cancer
  3. 5.1.2 Prostate Cancer
  4. 5.1.3 Colorectal Cancer
  5. 5.1.4 Lung Cancer
  6. 5.1.5 Others
  7. 5.2 Global Angiogenesis Modulators Sales by Application
  8. 5.2.1 Global Angiogenesis Modulators Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Angiogenesis Modulators Sales by Application (2021-2032)
  10. 5.2.3 Global Angiogenesis Modulators Sales Market Share by Application (2021-2032)
  11. 5.3 Global Angiogenesis Modulators Revenue by Application
  12. 5.3.1 Global Angiogenesis Modulators Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Angiogenesis Modulators Revenue by Application (2021-2032)
  14. 5.3.3 Global Angiogenesis Modulators Revenue Market Share by Application (2021-2032)
6 Global Angiogenesis Modulators Sales by Region
  1. 6.1 Global Angiogenesis Modulators Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Angiogenesis Modulators Sales by Region (2021-2032)
  3. 6.2.1 Global Angiogenesis Modulators Sales by Region (2021-2026)
  4. 6.2.2 Global Angiogenesis Modulators Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Angiogenesis Modulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Angiogenesis Modulators Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Angiogenesis Modulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Angiogenesis Modulators Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Angiogenesis Modulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Angiogenesis Modulators Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Angiogenesis Modulators Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Angiogenesis Modulators Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Angiogenesis Modulators Revenue by Region
  1. 7.1 Global Angiogenesis Modulators Revenue by Region
  2. 7.1.1 Global Angiogenesis Modulators Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Angiogenesis Modulators Revenue by Region (2021-2026)
  4. 7.1.3 Global Angiogenesis Modulators Revenue by Region (2027-2032)
  5. 7.1.4 Global Angiogenesis Modulators Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Angiogenesis Modulators Revenue (2021-2032)
  8. 7.2.2 North America Angiogenesis Modulators Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Angiogenesis Modulators Revenue (2021-2032)
  11. 7.3.2 Europe Angiogenesis Modulators Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Angiogenesis Modulators Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Angiogenesis Modulators Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Angiogenesis Modulators Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Angiogenesis Modulators Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Bayer Pharma AG (Germany)
  2. 8.1.1 Bayer Pharma AG (Germany) Company Information
  3. 8.1.2 Bayer Pharma AG (Germany) Business Overview
  4. 8.1.3 Bayer Pharma AG (Germany) Angiogenesis Modulators Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bayer Pharma AG (Germany) Angiogenesis Modulators Product Portfolio
  6. 8.1.5 Bayer Pharma AG (Germany) Recent Developments
  7. 8.2 Bionomics Ltd. (Australia)
  8. 8.2.1 Bionomics Ltd. (Australia) Company Information
  9. 8.2.2 Bionomics Ltd. (Australia) Business Overview
  10. 8.2.3 Bionomics Ltd. (Australia) Angiogenesis Modulators Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bionomics Ltd. (Australia) Angiogenesis Modulators Product Portfolio
  12. 8.2.5 Bionomics Ltd. (Australia) Recent Developments
  13. 8.3 CASI Pharmaceuticals, Inc. (USA)
  14. 8.3.1 CASI Pharmaceuticals, Inc. (USA) Company Information
  15. 8.3.2 CASI Pharmaceuticals, Inc. (USA) Business Overview
  16. 8.3.3 CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 CASI Pharmaceuticals, Inc. (USA) Angiogenesis Modulators Product Portfolio
  18. 8.3.5 CASI Pharmaceuticals, Inc. (USA) Recent Developments
  19. 8.4 Celgene Corporation (USA)
  20. 8.4.1 Celgene Corporation (USA) Company Information
  21. 8.4.2 Celgene Corporation (USA) Business Overview
  22. 8.4.3 Celgene Corporation (USA) Angiogenesis Modulators Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Celgene Corporation (USA) Angiogenesis Modulators Product Portfolio
  24. 8.4.5 Celgene Corporation (USA) Recent Developments
  25. 8.5 F.Hoffmann-La Roche AG (Switzerland)
  26. 8.5.1 F.Hoffmann-La Roche AG (Switzerland) Company Information
  27. 8.5.2 F.Hoffmann-La Roche AG (Switzerland) Business Overview
  28. 8.5.3 F.Hoffmann-La Roche AG (Switzerland) Angiogenesis Modulators Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 F.Hoffmann-La Roche AG (Switzerland) Angiogenesis Modulators Product Portfolio
  30. 8.5.5 F.Hoffmann-La Roche AG (Switzerland) Recent Developments
  31. 8.6 Genentech, Inc. (USA)
  32. 8.6.1 Genentech, Inc. (USA) Company Information
  33. 8.6.2 Genentech, Inc. (USA) Business Overview
  34. 8.6.3 Genentech, Inc. (USA) Angiogenesis Modulators Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Genentech, Inc. (USA) Angiogenesis Modulators Product Portfolio
  36. 8.6.5 Genentech, Inc. (USA) Recent Developments
  37. 8.7 AstraZeneca plc (UK)
  38. 8.7.1 AstraZeneca plc (UK) Company Information
  39. 8.7.2 AstraZeneca plc (UK) Business Overview
  40. 8.7.3 AstraZeneca plc (UK) Angiogenesis Modulators Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca plc (UK) Angiogenesis Modulators Product Portfolio
  42. 8.7.5 AstraZeneca plc (UK) Recent Developments
  43. 8.8 Amgen, Inc. (USA)
  44. 8.8.1 Amgen, Inc. (USA) Company Information
  45. 8.8.2 Amgen, Inc. (USA) Business Overview
  46. 8.8.3 Amgen, Inc. (USA) Angiogenesis Modulators Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Amgen, Inc. (USA) Angiogenesis Modulators Product Portfolio
  48. 8.8.5 Amgen, Inc. (USA) Recent Developments
  49. 8.9 GlaxoSmithKline plc (UK)
  50. 8.9.1 GlaxoSmithKline plc (UK) Company Information
  51. 8.9.2 GlaxoSmithKline plc (UK) Business Overview
  52. 8.9.3 GlaxoSmithKline plc (UK) Angiogenesis Modulators Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GlaxoSmithKline plc (UK) Angiogenesis Modulators Product Portfolio
  54. 8.9.5 GlaxoSmithKline plc (UK) Recent Developments
  55. 8.10 Eli Lilly and Company (USA)
  56. 8.10.1 Eli Lilly and Company (USA) Company Information
  57. 8.10.2 Eli Lilly and Company (USA) Business Overview
  58. 8.10.3 Eli Lilly and Company (USA) Angiogenesis Modulators Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly and Company (USA) Angiogenesis Modulators Product Portfolio
  60. 8.10.5 Eli Lilly and Company (USA) Recent Developments
  61. 8.11 Eisai (Japan)
  62. 8.11.1 Eisai (Japan) Company Information
  63. 8.11.2 Eisai (Japan) Business Overview
  64. 8.11.3 Eisai (Japan) Angiogenesis Modulators Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Eisai (Japan) Angiogenesis Modulators Product Portfolio
  66. 8.11.5 Eisai (Japan) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Angiogenesis Modulators Value Chain Analysis
  2. 9.1.1 Angiogenesis Modulators Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Angiogenesis Modulators Production Mode & Process
  6. 9.2 Angiogenesis Modulators Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Angiogenesis Modulators Distributors
  9. 9.2.3 Angiogenesis Modulators Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst